Blanco-Carmona Enrique, Paassen Irene, He Jiayou, DeMartino Jeff, Büllesbach Annette, Anderson Nadia, Buhl Juliane L, Federico Aniello, Mauermann Monika, Brok Mariël, Straathof Karin, Behjati Sam, Vibhakar Rajeev, Donson Andrew M, Foreman Nicholas K, Shaw McKenzie, Frühwald Michael C, Korshunov Andrey, Hasselblatt Martin, Thomas Christian, Franke Niels, Kranendonk Mariëtte Eg, Hoving Eelco W, Jäger Natalie, Johann Pascal D, Pfister Stefan M, Filbin Mariella G, Kool Marcel, Drost Jarno
Division of Pediatric Neurooncology, Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Neuro Oncol. 2025 Jul 28. doi: 10.1093/neuonc/noaf179.
Atypical teratoid rhabdoid tumors (ATRTs) are highly aggressive pediatric central nervous system tumors defined by the inactivation of the SMARCB1 gene. Despite the identification of three distinct molecular subtypes, each defined by unique clinical and molecular characteristics, no subtype-specific therapeutic strategies are currently available. This highlights an urgent need to deepen our understanding of the cellular heterogeneity and developmental origins of ATRTs.
We generated a comprehensive single-nucleus transcriptomic atlas of ATRT samples, integrated it with single-nucleus ATAC-seq and spatial transcriptomics data, and validated our findings experimentally using patient-derived ATRT tumoroid models.
Our analyses revealed distinct subtype-specific differentiation trajectories, each resembling different brain progenitor lineages. We identified key transcription factors that appear to drive these developmental pathways. Furthermore, a shared cycling, intermediate precursor cell (IPC)-like cell population, interspersed throughout tumors, was consistently present within all ATRT samples. We demonstrate that these subtype-specific differentiation pathways can be pharmacologically manipulated in patient-derived ATRT tumoroids. By directing tumor cells along their respective subtype-specific trajectories, we were able to induce a shift toward more differentiated, non-proliferative states.
Collectively, our findings show that ATRTs recapitulate fetal brain signaling programs in a subtype-specific manner. This work provides a framework for understanding ATRT heterogeneity and supports the feasibility of maturation-based therapeutic strategies tailored to the molecular subtype of the tumor.
非典型畸胎样横纹肌样肿瘤(ATRTs)是高度侵袭性的小儿中枢神经系统肿瘤,由SMARCB1基因失活定义。尽管已鉴定出三种不同的分子亚型,每种亚型都有独特的临床和分子特征,但目前尚无亚型特异性治疗策略。这凸显了迫切需要加深我们对ATRTs细胞异质性和发育起源的理解。
我们生成了ATRT样本的综合单核转录组图谱,将其与单核ATAC-seq和空间转录组学数据整合,并使用患者来源的ATRT类肿瘤模型通过实验验证了我们的发现。
我们的分析揭示了不同的亚型特异性分化轨迹,每种轨迹类似于不同的脑祖细胞谱系。我们确定了似乎驱动这些发育途径的关键转录因子。此外,在所有ATRT样本中始终存在一个共同的循环、中间前体细胞(IPC)样细胞群,散布在整个肿瘤中。我们证明,这些亚型特异性分化途径可以在患者来源的ATRT类肿瘤中进行药理学调控。通过引导肿瘤细胞沿着各自的亚型特异性轨迹,我们能够诱导其向更分化、非增殖状态转变。
总体而言,我们的研究结果表明,ATRTs以亚型特异性方式重现胎儿脑信号程序。这项工作为理解ATRT异质性提供了一个框架,并支持了针对肿瘤分子亚型的基于成熟的治疗策略的可行性。